Brain dopamine D4 receptors: Basic and clinical status

International Journal of Neuropsychopharmacology

Volumn 2, Issue 1, 1999, Pages 41-58

  Tarazi, Frank I ^a   Baldessarini, Ross J ^b  

^a MCLEAN HOSPITAL   (United States)

^b NONE

Author keywords

Antipsychotics; D4; Development; Dopamine; Genetics; mRNA; Receptors; Schizophrenia

Indexed keywords

EID: 0001826967     PISSN: 14611457     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1461145799001352     Document Type: Article

References (150)

1. Adamson MD, Kennedy J, Petronis A, Dean M, Virkkunen M, Linnoila M, Goldman D (1995). DRD4 dopamine receptor genotype and CSF monoamine metabolites in Finnish alcoholics and controls. American Journal of Medical Genetics 60, 199-205.
2. 4 dopamine receptor protein in the CNS using anti-receptor antisera. Brain Research 752, 26-34.
3. Amt J, Skarsfeldt T (1998). Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 18, 63-101.
4. 4 receptor variants. Journal of Neurochemistry 65, 1157-1165.
5. Baldessarini RJ (19S5). Chemotherapy in Psychiatry: Principles and Practice, 2nd ed. Cambridge, MA: Harvard University Press (and 3rd ed., In Press).
6. Baldessarini RJ (1996). Drugs and the treatment of psychiatric disorders. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG (Eds.), Goodman Gilman's The Pharmacologic Basis of Therapeutics (pp. 399-459). New York: McGraw-Hill.
7. Baldessarini RJ (1997). Dopamine receptors and clinical medicine. In Neve KA, Neve RL (Eds.), The Dopamine Receptors (pp. 457-498). Totowa, NJ: Humana Press.
8. Baldessarini RJ, Campbell A, Ben-Jonathan N, Ellingboe J, Zong R, Neumeyer JL (1994). Effects of aporphine isomers on rat prolactin. Neuroscience Letters 176, 269-271.
9. Baldessarini RJ, Frankenburg FR (1991). Clozapine - a novel antipsychotic agent. New England Journal of Medicine 324, 746-754.
10. Baldessarini RJ, Kula NS, Zong R, Neumeyer JL (1994). Receptor affinities of aporphine enantiomers in rat brain tissue. European Journal of Pharmacology 254, 199-203.
11. Baldessarini RJ, Tarazi FI (1996). Brain dopamine receptors: a primer on their current status, basic and clinical. Harvard Review of Psychiatry 3, 301-325.
12. Baldessarini RJ, Tarazi FI, Kula NS, Gardner DM (1997). Clozapine withdrawals: serotonergic or dopaminergic mechanisms - reply. Archives of General Psychiatry 54, 761-762.
13. Baldessarini RJ, Tarsy D (1979). Relationship of the actions of neuroleptic drugs to the pathophysiology of tardive dyskinesia. International Review of Neurobiology 21, 1-45.
14. Baldessarini RJ, Tarsy D (1980). Dopamine and the pathophysiology of dyskinesia induced by antipsychotic drugs. Annual Review of Neuroscience 3, 23-41.
15. 4 receptor gene in the susceptibility to Gilles de la Tourette syndrome in five Canadian families. American Journal of Medical Genetics 67, 301-305.
16. 4 dopamine receptor gene and measures of novelty seeking. Nature Genetics 12, 81-84.
17. 4 receptor mRNA in circulating human lymphocytes using nested polymerase chain reaction. Journal of Neuroimmunology 71, 139-144.
18. 4 receptor antagonist does not exhibit a neuroleptic-like profile in rodent behavioral tests. Journal of Pharmacology and Experimental Therapeutics 283, 1256-1263.
19. Brunello N, Masotto C, Steardo L, Markstein R, Racagani G (1995). New insights into the biology of schizophrenia through the mechanism of action of clozapine. Neuropsychopharmacology 13, 177-213.
20. Campbell A, Baldessarini RJ, Neumeyer JL (1993). Altered spontaneous behavior and sensitivity to apomorphine in rats following pretreatment with S(+)-aporphines or fluphenazine. Psychopharmacology 111, 351-358.
21. Campbell A, Baldessarini RJ, Teicher MH (1988). Decreasing sensitivity to neuroleptic agents in developing rats: evidence for a pharmacodynamic factor. Psychopharmacology 94, 46-51.
22. Campbell A, Baldessarini RJ, Teicher MH, Neumeyer JL (1985). S(+)Apomorphines: selective inhibition of excitatory effects of dopamine injected into the limbic system of the rat. Neuropharmacology 24, 391-399.
23. Campbell A, Baldessarini RJ, Teicher MH, Neumeyer JL (1986). Behavioral effects of apomorphine isomers in the rat: selective locomotor-inhibitory effects of S(+)N-n-propylnorapomorphine. Psychopharmacology 88, 158-164.
24. Campbell A, Yeghiayan S, Baldessarini RJ, Neumeyer JL (1991). Selective antidopaminergic effects of S(+)-N-propylnoraporphines in limbic vs extrapyramidal sites in rat brain: comparisons with typical and atypical antipsychotic agents. Psychopharmacology 103, 323-329.
25. Carlsson M, Carlsson A (1990). Interactions between glutamatergic and monoaminergic systems within the basal ganglia-implications for schizophrenia and Parkinson's disease. Trends in Neurosciences 13, 272-276.
26. 4 receptor gene in psychotic patients. Biological Psychiatry 34, 459-464.
27. Cepeda C, Levine MS (1998). Dopamine and N-methyl-D-aspartate receptor interactions in the neostriatum. Developmental Neuroscience 20, 1-18.
28. 4 dopamine receptor-mediated signaling events determined in transfected chinese hamster ovary cells. Journal of Biological Chemistry 269, 11813-11819.
29. 4 antagonist L-745,870 as evaluated ethologically (abstract). Schizophrenia Research 29, 168.
30. 2 receptors. Journal of Neurochemistry 59, 627-635.
31. Creese I, Burt D, Snyder S (1976). Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192, 481-483.
32. 4 dopamine receptor genes on chromosome 11. American Journal of Psychiatry 151, 1202-1206.
33. 4 dopamine receptor in rat brain. Neurochemical Research 22, 401-407.
34. 4 dopamine receptor in rat brain with sequence-specific antibodies. Molecular Brain Research 45, 1-12.
35. 4 receptor genes and schizophrenia defined by several diagnostic systems. Biological Psychiatry 40, 419-421.
36. 1 receptor (D4DR) exon III polymorphism associated with the human personality trait of novelty seeking. Nature Genetics 12, 78-80.
37. 4 receptor in the induction of behavioral sensitization to amphetamine and accompanying biochemical and molecular adaptations: treatment with antipsychotic drugs. Journal of Pharmacology and Experimental Therapeutics 286, 497-508.
38. 4 dopamine receptors in post-mortem human brain. Neuroscience Letters 175, 17-20.
39. Florijn WJ, Tarazi FI, Creese I (1997). Dopamine receptor subtypes: differential regulation following 8 months treatment with antipsychotic drugs. Journal of Pharmacology and Experimental Therapeutics 280, 561-569.
40. 4.4 receptor. British Journal of Pharmacology 124, 889-896.
41. 4 dopamine receptor (DRD4) maps to distal lip close to HRAS. Genomics 13, 208-210.
42. 4 agonists. Journal of Medicinal Chemistry 40, 1771-1772.
43. 4 sites in schizophrenic brains. European Journal of Pharmacology 314, R3-R5.
44. 4 receptor. European Journal of Pharmacology 314, 229-233.
45. 4 receptor antagonist. NeuroReport 7, 2543-2546.
46. Jackson DM, Westlind-Danielsson A (1994). Dopamine receptors: molecular biology, biochemistry and behavioral aspects. Pharmacology and Therapeutics 64, 291-369.
47. Jones EG (1984). Laminar distribution of cortical efferent cells. In Peters A, Jones Eg (Eds), Cerebral Cortex, vol. 1, Cellular Components of the Cerebral Cortex (pp. 521-553). New York: Plenum Press.
48. 4 receptor gene polymorphisms. American Journal of Psychiatry 154, 697-699.
49. Kane JM, Honigfeld G, Singer J, Meltzer HY (1988). Clozapine for the treatment resistant schizophrenic: double-blind comparison with chlorpromazine. Archives of General Psychiatry 45, 789-796.
50. Kebabian JW, Calne DG (1979). Multiple receptors for dopamine. Nature 277, 93-96.
51. Kebabian JW, Tarazi FI, Kula NS, Baldessarini RJ (1997). Compounds selective for dopamine receptor subtypes. Drug Discovery Today 2, 333-340.
52. Kelley AE, Domesick VB (1982). The distribution of the projection from the hippocampal formation to the nucleus accumbens in the rat: an anterograde and retrograde horseradish peroxidase study. Neuroscience 7, 2321-2335.
53. 4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. Archives of General Psychiatry 54, 567-572.
54. 4-selective dopamine receptor ligand. European Journal of Pharmacology 331, 333-336.
55. 3 dopamine receptors. Cellular and Molecular Neurobiology 14, 185-191.
56. 4-selective radioligands. European Journal of Pharmacology.
57. 4 receptor. Journal of Medicinal Chemistry 39, 1941-1942.
58. 4 receptors expressed in CHO cells. Life Sciences 60, 1-100.
59. Kusumi I, Ishikane T, Matsubara S, Koyama T (1995). Long-term treatment with halperidol or clozapine does not affect dopamine D4 receptors in rat frontal cortex. Journal of Neural Transmission 101, 231-235
60. 4 receptor gene polymorphism is associated with attention deficit hyperactivity disorder. Molecular Psychiatry 1, 121-124.
61. 2 receptor selectivity of dopamine receptor antagonists: possible therapeutic implications. European Journal of Pharmacology 236, 483-486.
62. 3H]NGD 94-1 study. Molecular Psychiatry 3, 528-533.
63. 2-type dopamine receptors in postmortem human brain sections from normal and schizophrenic subjects. NeuroReport 7, 1945-1948.
64. 2-Family receptor distribution in human postmortem tissue: an autoradiographic study. NeuroReport 6, 2505-2512.
65. 4.4 receptors. European Journal of Pharmacology 301, R11-R13.
66. 4 receptor. Journal of Neurochemistry 68, 804-812.
67. 2-dopaminergic receptors in the primate cerebral cortex. Proceedings of the National Academy of Sciences, USA 91, 4353-4356.
68. Lidow MS, William GV, Goldman-Rakic PS (1998). The cerebral cortex: a case for a common site of action of antipsychotics. Trends in Pharmacological Science 19, 136-140.
69. 4valine194glycine, is insensitive to dopamine and clozapine: report of a homozygous individual. American Journal of Medical Genetics 61, 277-282.
70. 4 using haplotype relative risk. Human Heredity 44, 328-336.
71. 4 receptor and transporter gene polymorphisms and mood disorders. Journal of Affective Disorders 40, 7-13.
72. 4 receptor antagonists reverse apomorphine-induced blockade of prepulse inhibition. Psychopharmacology 135, 194-200.
73. 4 receptor. Molecular Brain Research 29, 157-162.
74. 4 receptor in human cerebral cortex and striatum. Journal of Neurochemistry 66, 915-919.
75. Meador-Woodruff JH, Damask SP, Wang J, Haroutunian V, Davis KL, Watson SJ (1996). Dopamine receptor mRNA expression in human striatum and neocortex. Neuropsychopharmacology 15, 17-29.
76. Meador-Woodruff JH, Damask SP, Watson SJ (1994a). Differential expression of autoreceptors in the ascending dopamine systems of the human brain. Proceedings of the National Academy of Sciences, USA 91, 8296-8301.
77. Meador-Woodruff JH, Grandy DK, Van Tol HHM, Damask SP, Little KY, Civelli O, Watson SJ (1994b). Dopamine receptor gene expression in the human medial temporal lobe. Neuropsychopharmacology 10, 239-248.
78. Meador-Woodruff JH, Haroutunian V, Powchik P, Davidson M, Davis KL, Watson SJ (1997). Dopamine receptor transcript expression in striatum and prefrontal and occipital cortex. Focal abnormalities in orbitofrontal cortex in schizophrenia. Archives of General Psychiatry 54, 1089-1095.
79. 4 receptor inhibits an L-type calcium current in cerebellar granule cells. Neuroscience 68, 107-116.
80. 4 receptor selective antagonist. Journal Pharmacology and Experimental Therapeutics 279, 1392-1403.
81. Meltzer HY, Nash JF (1991). Effects of antipsychotic drugs on serotonin receptors. Pharmacological Reviews 43, 587-604.
82. 1 receptors in GABAergic neurons of the primate brain. Nature 381, 245-248.
83. 4 gene in post-mortem frontal cortex from controls and schizophrenics. Neuroscience Leiters 219, 163-166.
84. 4 gene expression in human brain. Neuroscience Letters 234, 147-150.
85. 4 dopamine receptors in postmortem striatum from patients with schizophrenia. Journal of Neuroscience 15, 2186-2191.
86. 4 receptor in rat brain. Developmental Brain Research 90, 180-183.
87. 4 receptor polymorphism and schizophrenia. Lancet 341, 689-690.
88. 4 receptor gene polymorphisms. American Journal of Medical Genetics 54, 361-364.
89. Nemeroff CB, Kilts CD, Levant B, Bissette G, Campbell A, Baldessarini RJ (1991). Effects of aporphine isomers and haloperidol on regional concentrations of neurotensin in rat brain. Neuropsychopharmacology 4, 27-33.
90. Neve KA, Neve RL (1997). The Dopamine Receptors. Totowa, NJ: Humana Press.
91. 4.4 receptors: actions of antiparkinsonina and antipsychotic agents. Journal of Pharmacology and Experimental Therapeutics 282, 181-191.
92. 4 receptor antagonists: synthesis and structure-activity relationships of (S)(+)-N-(1-benzyl-3-pyrrolidinyl)-5-chloro-4-[(cyclopropylcarbonyl)-amino]-2- methoxybenzamide (YM-43611) and related compounds. Journal of Medicinal Chemistry 39, 2764-2772.
93. 2A receptor and alpha-1 adrenoceptor antagonist (R)-(+)-2-amino-4-(4-fluorophenyl)-5-[1-[4-(4-fluorophenyl)-4-oxobutyl] pyrrolidin-3-yl]thiazole (NRA-0045). Journal of Pharmacology and Experimental Therapeutics 282, 56-63.
94. 4 and 5-hydroxytryptamine-2A receptor antagonist, in rats. British Journal of Pharmacology 121, 515-525.
95. 4 receptor: sequence, gene structure and demonstration of expression in the cardiovascular system. New Biologist 4, 137-146.
96. 4 receptor. Molecular Pharmacology 50, 1658-1664.
97. 4 receptor gene and schizophrenia. American Journal of Medical Genetics 60, 452-455.
98. 3H]NGD-94-1. Journal of Pharmacology and Experimental Therapeutics 282, 1020-1027.
99. 4 dopamine receptor gene does not predict clozapine response. Archives of General Psychiatry 51, 912-917.
100. 4 receptors in drug-treated schizophrenia. European Journal of Pharmacology 281, R5-R6.
101. 4 receptor exon 3 repeat polymorphism in Parkinson's disease. Clinical Genetics 54, 33-38.
102. 4 receptor gene. Neuropsychopharmacology 15, 491-496.
103. 4 receptor mRNA in postmortem brains of schizophrenics and controls. Schizophrenia Research 20, 171-174.
104. 4 dopamine receptor affinity does not distinguish between typical and atypical antipsychotic drugs. Psychopharmacology 120, 365-368.
105. 4 receptors are supersensitive to ethanol, cocaine, and methamphetamine. Cell 90, 991-1001.
106. 4 receptor antagonists. Expert Opinions on Therapeutic Patents 8, 383-393.
107. 4 receptor antagonist. Bioorganic Medical and Chemical Letters 8, 725-730.
108. 4 receptors by 2-fold in rats. European Journal of Pharmacology 289, 67-72.
109. Seeger TF, Seymour PA, Schmidt AW, Zorn SH, Schulz DW, Lebel LA, Mclean S, Guanowsky V, Howard HR, Löwe JA III, Heym J (1995). Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonists activity. Journal of Pharmacology and Experimental Therapeutics 275, 101-113.
110. Seeman P (1995). Therapeutic receptor-blocking concentrations of neuroleptics. International Clinical Psychopharmacology 10 (Suppl.), 5-13.
111. 4 receptors. Neuropsychopharmacology 16, 93-110.
112. 3H]benzquinoline. Synapse 25, 137-146.
113. 4 receptors elevated in schizophrenia. Nature 365, 441-445.
114. Seeman P, Lee T, Chau-Wong M, Wong K (1976). Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 261, 717-719.
115. 4 receptors bind inactive (+)-aporphines, suggesting neuroleptic role; sulpiride not stereoselective. European Journal of Pharmacology 233, 173-174.
116. 4 receptor subtypes and response to clozapine. Lancet 341, 116.
117. 4 Dopamine receptor-mediated phospholipid methylation and its implications for mental illnessess such as schizophrenia. Molecular Psychiatry.
118. 3) as a target for neuroleptics. Nature 347, 146-151.
119. 4 dopamine receptor mRNA in postmortem schizophrenic brain. Molecular Brain Research 53, 112-119.
120. 3H]racIopride binding in postmortem caudate nucleus of subjects with schizophrenia or major depression. Brain Research 681, 109-116.
121. 1. Nature 350, 610-614.
122. Surmeier DJ, Song W-J, Van Z (1996). Coordinated expression of dopamine receptors in neostriatal medium spiny neurons. Journal of Neuroscience 16, 6579-6591.
123. 4 receptor. Neuroscience Letters 199, 69-72.
124. 4 (DRD4) gene with a refined phenotype of attention deficit hyperactivity disorder (ADHD), a family-based approach. Molecular Psychiatry 3, 38-41.
125. Swerdlow NR, Braff DL, Taaid N, Geyer MA (1994). Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients. Archives of General Psychiatry 51, 139-154.
126. 4 receptor. Journal of Pharmacology and Experimental Therapeutics 282, 1011-1019.
127. Tarazi FI, Baldessarini RJ (In Press). Regional localization of dopamine and ionotropic glutamate receptor subtypes in striatolimbic grain regions. Journal of Neuroscience Research.
128. 4-like receptors. Neuroscience 87, 1-4.
129. Tarazi FI, Campbell A, Baldessarini RJ (1998b). Effects of hippocampal kainic acid lesion on striatolimbic ionotropic glutamate NMDA, AMPA and KA receptors. Neuroscience Letters 250, 13-16
130. 4-like receptors. Neuroscience 83, 169-176.
131. Tarazi FI, Campbell A, Yeghiayan SK, Baldessarini RJ (1998d). Localization of glutamate receptor subtypes in caudateputamen and nucleus accumbens septi : comparison of NMDA, AMPA and kainate receptors. Synapse 30, 227-235.
132. Tarazi FI, Florijn WJ, Creese I (1996). Regulation of ionotropic glutamate receptors following subchronic and chronic treatment with typical and atypical antipsychotics. Psychopharmacology 128, 371-379.
133. Tarazi FI, Florijn WJ, Creese I (1997a). Differential regulation of dopamine receptors following chronic typical and atypical antipsychotic drug treatment. Neuroscience 78, 985-996.
134. 4 receptors in rat forebrain. NeuroReport 8, 3423-3426.
135. 2-Iike receptors. Developmental Brain Research 110, 227-233.
136. Tarazi FI, Tomasini EC, Baldessarini RJ (1998f). Postnatal development of dopamine and serotonin transporters in rat caudate-putamen and nucleus acumbens septi. Neuroscience letters 254, 21-24.
137. 1-like receptors in cortical and striatolimbic brain regions: an autoradiographic study. Developmental Neuroscience.
138. 4-like dopamine receptors. Neuropsychophannacology 17, 186-196.
139. 4-like dopamine receptors: common targets for typical, atypical and experimental antipsychotics. Progress in Neuro-Psychopharmacology and Biological Psychiatry 22, 693-707.
140. Teicher MH, Barber NI, Gelbard HA, Gallitano AL, Campbell A, Marsh E, Baldessarini RJ (1993). Developmental differences in acute nigrostriatal and mesocorticolimbic system response to haloperidol. Neuropsychopharmacology 9, 147-156.
141. 3 autoreceptors on nigrostriatal neurons analyzed by antisense knockdown in vivo. Journal of Neuroscience 17, 2519-2530.
142. 4 receptor (D4DR) exon III seven-repeat alleles in Baltimore longitudinal study of aging participants. Molecular Psychiatry 2, 417-419.
143. 4 receptor gene with high affinity for the antipsychotic clozapine. Nature 350, 614-619.
144. 4 receptor variants in the human population. Nature 358, 149-152.
145. Weinberger DR (1987). Implications of normal brain development for the pathogenesis of schizophrenia. Archives of General Psychiatry 44, 660-669.
146. 4 receptor mediated inhibition of potassium current in neurohypophysial nerve terminals. Journal of Pharmacology and Experimental Therapeutics 284, 542-548.
147. 4 receptor ligands: relation to antipsychotic action. European Journal of Pharmacology 351, 273-286.
148. 4 receptor antagonists: 1-aryloxy-3-(4-aryloxypiperidinyl)-2-propanols. Bioorganic and Medicinal Chemistry Letters 7, 1377-1380.
149. 4 receptor agonist (abstract 271.11). Society for Neuroscience Abstracts 23, 685.
150. 4 dopamine antagonist with an in vitro and in vivo profile suggestive of an atypical antipsychotic (abstract 697.1). Society for Neuroscience Abstracts 22, 1771.